Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
myramistin
- Development stage
- Unknown
- Lead developer
- Infamed
- Modality
- Small Molecules
- Administration
- Intranasal, Ophthalmic, Otic, Topical
01
Overview
Myramistin (commonly known as Miramistin) is a synthetic, broad-spectrum topical antiseptic and cationic surfactant originally developed in the Soviet Union. Chemically classified as a quaternary ammonium compound, myramistin acts by directly interacting with and disrupting microbial cell membranes, leading to cytolysis and cell death. It exhibits robust antimicrobial activity against Gram-positive and Gram-negative bacteria (including multidrug-resistant hospital strains), as well as various fungi and complex viruses. Myramistin is used topically for the treatment and prophylaxis of infectious and inflammatory conditions, including superficial pyoderma, wound infections, otorhinolaryngological (ENT) infections, and mucosal or oral infections. It is developed and manufactured by Infamed and has been evaluated in clinical trials sponsored by Valenta Pharm.
- Brand names
- MiramistinOkomistin
- Other names
- benzyldimethyl(3-tetradecamidopropyl)ammonium chloridebenzyldimethyl[3-(myristoilamino)propyl]ammonium chloridebenzyldimethyl[3-(myristoylamino)propyl]ammonium chloridebenzyl-dimethyl-[3-(tetradecanoylamino)propyl]azaniumbenzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium chloridemiramistinMiramystinmyramstinmyristamidopropyl dimethylbenzylammonium chloride
02
Targets
Neuraminidase
Beyond the preview
Go deeper on myramistin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on myramistin.